Observational Studies of the Application of Bevacizumab in HER2-negative Breast Cancer Neoadjuvant Chemotherapy (BIBC)

LiNanlin,Ph.D, Chief Physician,Clinical Professor

Status: Unknown

Conditions: Molecular Targeted Therapy; Breast Cancer; Bevacizumab; Neoadjuvant Chemotherapy

Treatments: Drug: bevacizumab

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT01652560

QTDS-01

Details and patient eligibility

About

• The purpose of this study is to evaluate the efficacy and safety of the application of bevacizumab combined neoadjuvant chemotherapy in HER2-negative breast cancer.

Enrollment: 50 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• HER2-negative breast cancer patients
• Without surgery
• Plans to neoadjuvant chemotherapy

Exclusion criteria

• HER2-positive breast cancer patients
• Post-operative patients

Trial design

50 participants in 1 patient group

bevacizumab combined neoadjuvant chemotherapy

Treatment:

Drug: bevacizumab